Peptide Therapy Insights

FDA's Crackdown on Compounded GLP-1 Drugs: What Patients Need to Know in 2026

The FDA removed semaglutide and tirzepatide from its drug shortage list in early 2025, ending the compounding exemption that had allowed hundreds of pharmacies to produce GLP-1 copies at lower cost. Here's what that means for your access, your wallet, and your options right now.

FDA Peptide Regulations Explained: What's Actually Regulated in 2026

The FDA's regulatory framework for peptides is more complex — and more consequential — than most patients realize. Here's what's actually regulated, what isn't, and what you need to know before starting any peptide therapy in 2026.

Somatostatin Receptor Role in Treating Small Bowel Tumors

Somatostatin receptor assessment is crucial for treating small bowel neuroendocrine tumors with peptide receptor radionuclide therapy. Learn how this approach impacts patient care.

New Technique Enhances Peptide Therapeutics with Non-Natural Amino Acids

A groundbreaking technique now enables the synthesis of non-natural amino acids, potentially revolutionizing peptide therapeutics. Learn how this could impact treatment options.

Optimizing Chromatography for Peptide Purification: Key Insights

Discover how advancements in chromatography optimization are enhancing the purification of therapeutic peptides. This could impact the quality and availability of peptide therapies for patients.

FDA Implements New Restrictions on Mass-Marketed Compounded GLP-1 Products

Injectable Peptide Therapy Gains Mainstream Acceptance in 2025

GLP-1 Market Growth Projected to Hit $33.26 Billion by 2030: Implications for Obesity and Diabetes Therapies

Semaglutide vs. Tirzepatide Side Effects: Complete Head-to-Head Comparison (2026)

Comprehensive comparison of semaglutide (Wegovy) and tirzepatide (Zepbound) side effects, including nausea rates, GI tolerability, FDA status, cost, and how to choose between them.